Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
M&A / Property Routine +

High Tide's German Subsidiary Remexian Pharma Showcases Exclusive Canadian Medical Cannabis Brand Partnerships at Mary Jane Berlin 2026

Remexian distribution partnerships reinforce German growth thesis, but stock has already priced in the catalyst.

By The Northwire Desk — AI Analysis Jun 17, 2026 · 06:00 HITI · 3.53 High Tide Inc.
Executive Summary
  • High Tide's majority-owned German subsidiary, Remexian Pharma GmbH, showcased exclusive distribution partnerships with six leading Canadian medical cannabis brands at the Mary Jane Berlin 2026 trade show.
  • The partnerships bring premium Canadian brands (Tribal, Highly Dutch Organic, Weed Me, The Loud Plug, Joi Botanicals, Castle Rock Farms) to German patients and pharmacies.
  • Remexian holds a 14% share of the German medical cannabis market and is licensed to import from 19 countries.
  • CEO Raj Grover emphasized that exclusive distribution agreements and procurement capabilities are creating a competitive advantage to capture greater market share.
  • The announcement is a business development/partnership update, not a financial results release.
Material Impact
  • The partnership announcement is operationally positive but fundamentally incremental. It validates the Remexian growth thesis already priced into the Q2 earnings beat.
  • The stock's +10.9% run-up into the print indicates the market anticipated a positive catalyst. The news does not represent a fundamental re-rating or a surprise beat/miss.
  • Given the credible execution track record, consistent margin expansion, and disciplined capital allocation, the news is supportive but not transformative. The asymmetric risk is limited because the positive sentiment is already reflected in the price action.
HITI · Price
Company Overview

High Tide Inc. operates a globally diversified cannabis platform. Its core Canadian bricks-and-mortar segment, Canna Cabana, operates 228 retail locations across five provinces, holding approximately 12% of the Canadian cannabis retail market. The international segment, Remexian Pharma GmbH (51% owned), is a leading medical cannabis distributor in Germany with a 14% market share. The company also maintains a U.S. hemp-derived CBD subsidiary (NuLeaf Naturals) and is exploring European expansion.

Read the original news release →

More from High Tide Inc.

Jun 15, 2026 · 16:00

First net income and record EBITDA beat expectations, but same-store sales decline and flat price action suggest skepticism remains.

Earnings Jun 15, 2026 · 15:31

High Tide receives approval for $40M of facilities

Financings Jun 15, 2026 · 06:00

High Tide to Acquire Northern Helm, Adding Four Established Retail Cannabis Stores in Ontario

M&A / Property Jun 10, 2026 · 11:00

Routine store expansion in line with guidance; market remains skeptical as stock drifts lower post-Q1 beat.

Production / Operations May 11, 2026 · 06:00

Insider buying and surging German medical cannabis market share signal conviction as High Tide shores up a Big Five bank credit line.

Production / Operations May 06, 2026 · 06:00

High Tide Germany Distribution Surges as Bank Financing Validates Liquidity

Production / Operations